Migraine Disorders
212
23
29
127
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
53 trials with published results (25%)
Research Maturity
127 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.7%
12 terminated out of 212 trials
91.4%
+4.9% vs benchmark
29%
61 trials in Phase 3/4
42%
53 of 127 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 127 completed trials
Clinical Trials (212)
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Migraine Manager (R01)
Mind Body Balance for Pediatric Migraine
Responding With Evidence and Access for Childhood Headaches
Videonystagmography and Vestibular Migraine
Fremanezumab, Migraine and Sleep
EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
Therapy for Migraine Prevention in Children 6-11 Years of Age
Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
Amylin-Induced Migraine Attacks Without Aura
Emotional Awareness and Expression Therapy (EAET) as a Novel Migraine Treatment
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
Determining the Utility of a Behavioral Intervention in Chronic Migraine
Effects of tDCS and Physical Therapy in Chronic Migraine
Migraine Medication Effects on Urinary Symptoms
(Italian Migraine Registry, I-GRAINE-NEW)
Mind and Body Approaches to Pain Reduction in Youth With Migraine
Understanding the Pathophysiology of Migraine Pain
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks